Cadrenal Therapeutics, Inc. Common Stock (CVKD)vsNovartis AG ADR (NVS)
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$4.44
+3.02%
HEALTHCARE · Cap: $12.90M
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
CVKD
Avoid16
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CVKD.
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : CVKD
CVKD has a balanced fundamental profile.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : CVKD
The primary concerns for CVKD are Revenue Growth, EPS Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
CVKD profiles as a value stock while NVS is a declining play — different risk/reward profiles.
CVKD carries more volatility with a beta of 1.83 — expect wider price swings.
CVKD is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 16/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cadrenal Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies for renal diseases and kidney-related disorders. Utilizing its proprietary drug platforms, the company is committed to addressing significant unmet medical needs through a robust pipeline of drug candidates currently in advanced clinical trials. With a strong emphasis on scientific innovation and patient-centric solutions, Cadrenal is poised to deliver transformative treatments that could significantly enhance renal health outcomes, underscoring its potential for substantial growth in the evolving biopharmaceutical landscape.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?